Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Influenza Like Illness

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Influenza Like Illness. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-001857-29 Sponsor Protocol Number: V130_14 Start Date*: 2019-03-13
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to...
    Medical condition: Prophylaxis of influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001863-11 Sponsor Protocol Number: EWO-ISO-2014/1 Start Date*: 2014-09-24
    Sponsor Name:Ewopharma AG.
    Full Title: A Phase 4, Randomised, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy of Isoprinosine® in Comparison With Placebo in Subjects With Confirmed Acute Respiratory Viral Infect...
    Medical condition: Acute Respiratory Viral Infections due to influenza A or B virus, RSV, adenovirus, or parainfluenza virus 1 or 3
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003284-31 Sponsor Protocol Number: NV20236 Start Date*: 2006-12-18
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: An open label multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in children
    Medical condition: Seasonal prophylaxis of influenza in immunocompromised subjects
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Influenza LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001103-77 Sponsor Protocol Number: FLU007INVICTUS Start Date*: 2017-09-05
    Sponsor Name:Vaccitech Limited
    Full Title: A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10016790 Flu LLT
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004072-19 Sponsor Protocol Number: Acti-INSP-001 Start Date*: 2012-12-28
    Sponsor Name:Vectura GmbH
    Full Title: A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patie...
    Medical condition: Influenza A and B
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001231-51 Sponsor Protocol Number: GQM05 Start Date*: 2014-05-20
    Sponsor Name:Sanofi Pasteur
    Full Title: Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 Months
    Medical condition: Prevention of influenza infection in children aged 6 to 35 months
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-004721-24 Sponsor Protocol Number: QHD00014 Start Date*: 2020-09-07
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Efficacy, Immunogenicity, and Safety of High-Dose Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months through 35 Months of Age
    Medical condition: Prevention of influenza infection in children 6 months through 35 months of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2013-001051-12 Sponsor Protocol Number: 11RM013 Start Date*: Information not available in EudraCT
    Sponsor Name:Nottingham University Hospitals NHS Trust
    Full Title: Early low dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo controlled trial
    Medical condition: Influenza-like illness
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001008-49 Sponsor Protocol Number: NV22155 Start Date*: 2016-09-30
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003786-41 Sponsor Protocol Number: V70P5 Start Date*: 2007-10-22
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vacci...
    Medical condition: no medical, condition: healthy,
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) IT (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000218-12 Sponsor Protocol Number: V118_05 Start Date*: 2013-09-17
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus...
    Medical condition: Prophylaxis for influenza virus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001894-26 Sponsor Protocol Number: CP-PRO-QVLP-014 Start Date*: 2018-10-18
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Ad...
    Medical condition: Seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-000425-40 Sponsor Protocol Number: GV29893 Start Date*: 2016-08-03
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION...
    Medical condition: acute uncomplicated seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10022002 Influenza A virus infection LLT
    19.0 100000004862 10022001 Influenza (epidemic) LLT
    19.0 100000004862 10016790 Flu LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002468-24 Sponsor Protocol Number: NV20234 Start Date*: 2008-02-13
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza
    Medical condition: To investigate the optimal therapy for influenza in immunocompromised transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Influenza LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FR (Completed) BE (Completed) HU (Completed) LT (Completed) CZ (Completed) EE (Completed) IT (Completed) GR (Prematurely Ended) BG (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000468-27 Sponsor Protocol Number: BVX-010 Start Date*: 2018-07-04
    Sponsor Name:BiondVax Pharmaceuticals Ltd.
    Full Title: A pivotal, multicentre, randomized, modified double-blind, placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine administered intramuscularly tw...
    Medical condition: Flu vaccination
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) LV (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001638-12 Sponsor Protocol Number: mRNA-1010-P302 Start Date*: 2022-09-29
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older.
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) EE (Completed) BG (Completed) DK (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002633-11 Sponsor Protocol Number: NV25719 Start Date*: 2013-01-24
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: An open label, randomised, adaptive, multicenter, pharmacokinetic/pharmacodynamic, phase Ib, study of oseltamivir (Tamiflu®) in the treatment of influenza in immunocompromised children, between 0-1...
    Medical condition: Treatment of influenza in immunocompromised paedriatric patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FI (Completed) IT (Completed) PL (Completed) BE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005929-49 Sponsor Protocol Number: VX11-787-101 Start Date*: 2012-02-20
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus
    Medical condition: Influenza A
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006263-23 Sponsor Protocol Number: ML20910 Start Date*: 2006-12-05
    Sponsor Name:ROCHE
    Full Title: Efficacy of Oseltamivir treatment in laboratory- confirmed influenza: evaluation of effect on viral shedding and on serum and cytoplasmatic inflammatory cytokine concentration.
    Medical condition: Influenza type A and B virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001514-97 Sponsor Protocol Number: 114541 Start Date*: 2015-05-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 3, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’ quadrivalent, inactivated, split virion,...
    Medical condition: Healthy volunteers (Immunization against influenza in male and female subjects 3 to 8 years of age inclusive)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA